Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 2, 2005, Pages 877-887

  McCollum, Geniece ^a   Keng, Peter C ^a   States, J Christopher ^b   McCabe Jr , Michael J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ARSENITE SODIUM; CAMPTOTHECIN; CARCINOGEN; TOXIC SUBSTANCE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL DEATH; DNA CONTENT; DNA REPAIR; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MYELOID LEUKEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TARGET CELL DESTRUCTION;

APOPTOSIS; ARSENITES; CELL CYCLE; CELL DIVISION; G2 PHASE; HUMANS; LEUKEMIA, MYELOID; MITOSIS; U937 CELLS;

EID: 18044388946     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.080713     Document Type: Article

References (39)

1. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177-2196.
2. Anderson HJ, de Jong G, Vincent I, and Roberge M (1998) Flow cytometry of mitotic cells. Exp Cell Res 238:498-502.
3. Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6 (Suppl 2):1-2.
4. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, and Gisslinger H (2001) Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 112:783-786.
5. Begg AC, McNally NJ, Shrieve DC, and Karcher H (1985) A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6:620-626.
6. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, et al. (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14:262-270.
7. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, and Chen GQ (2003) Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 17:1333-1337.
8. Chen Z, Chen GQ, Shen ZX, Chen SJ, and Wang ZY (2001) Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 38:26-36.
9. Chou S, Odin M, Sage GW, and Little S (2000) Toxicological profile for arsenic, in Agency for Toxic Substances and Disease Registry, Atlanta, GA.
10. de The H and Chelbi-Alix MK (2001) APL, a model disease for cancer therapies? Oncogene 20:7136-7139.
11. Donaldson KL, McShea A, Wahl AF (1997) Separation by counterflow centrifugal elutriation and analysis of T- and B-lymphocytic cell lines in progressive stages of cell division cycle. J Immunol Meth 203:25-33.
12. Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, and Traganos F (2002) Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 1:201-209.
13. Howell BJ, Hoffman DB, Fang G, Murray AW, and Salmon ED (2000) Visualization of Mad2 dynamics at kinetochores, along spindle fibers and at spindle poles in living cells. J Cell Biol 150:1233-1250.
14. Huang C, Ma WY, Li J, and Dong Z (1999) Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59:3053-3058.
15. Jing Y, Dai J, Chalmers-Redman KM, Tatton WG, and Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111.
16. Li YM and Broome JD (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59:776-780.
17. Ling YH, Jiang JD, Holland JF, and Perez-Soler R (2002) Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 62:529-538.
18. Liu M, Lee M-H, Cohen M, Bommakanti M, and Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153.
19. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, and Han ZC (1999) Effect of arsenic trioxide on viability, proliferation and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 27:845-852.
20. McCabe MJ Jr, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ Jr, and States JC (2000) Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment and cell cycle phase. J Pharmacol Exp Ther 295:724-733.
21. Miller WH Jr, Schipper HM, Lee JS, Singer J, and Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903.
22. Murray A and Hunt T (1993) The Cell Cycle. Oxford University Press, Oxford, UK.
23. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, and Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279.
24. 2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 286:726-734.
25. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, and Lee YY (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21 and apoptosis. Cancer Res 60:3065-3071.
26. Reglinski J (1998) Environmental and medicinal chemistry of arsenic, antimony and bismuth, in Chemistry of Arsenic, Antimony, and Bismuth (Norman NC ed) pp 403-440, Blackie Academic and Professional, London, UK.
27. Rego EM, He LZ, Warrell RP Jr, Wang ZG, and Pandolfi PP (2000) Retinoic acid (RA) and As203 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97:10173-10178.
28. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, and Fermand JP (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59:1041-1048.
29. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, and Lee YY (1999) Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 265:400-404.
30. Soignet SL (2001) Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 (Suppl 2):11-16.
31. States JC, Reiners JJ Jr, Pounds JG, Kaplan DJ, Beauerle BD, McNeely SC, Mathieu P, and McCabe MJ Jr (2002) Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. Toxicol Appl Pharmacol 180:83-91.
32. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, and Hirai H (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378-2383.
33. Sundstrom C and Nilsson K (1976) Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565-577.
34. Wang Z-G, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, and Pandolfi PP (1998) Arsenic trioxide and melar-soprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497-1504.
35. Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48 (Suppl 1):S72-76.
36. Zhang TC, Cao EH, Li JF, Ma W, and Qin JF (1999) Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35:1258-1263.
37. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, and Ohno R (1998) The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383-1391.
38. Zhu J, Lallemand-Breitenbach V, and de The H (2001) Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265.
39. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, et al. (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91:772-778.